Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCT Nuvectis Pharma, Inc.

Pre-Mkt 11-10 09:14:28 EST

21.02

+0.11

+0.53%

High22.18	Low19.72	Vol385.12K
Open21.09	D1 Closing20.91	Amplitude11.76%
Mkt Cap722.85M	Tradable Cap483.68M	Total Shares34.39M
T/O8.12M	T/O Rate1.67%	Tradable Shares23.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCT","market":"US","secType":"STK","nameCN":"Nuvectis Pharma, Inc.","latestPrice":21.02,"timestamp":1794258000000,"preClose":20.91,"halted":0,"volume":385119,"delay":0,"changeRate":0.005260640841702508,"floatShares":23010541,"shares":34388900,"eps":-2.025841,"marketStatus":"Pre-Mkt","change":0.11,"latestTime":"11-10 09:14:28 EST","open":21.09,"high":22.1793,"low":19.72,"amount":8117792.460539999,"amplitude":0.117614,"askPrice":22,"askSize":590,"bidPrice":16.83,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.025841,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1794321000000},"marketStatusCode":1,"adr":0,"listingDate":1638334800000,"exchange":"NASDAQ","adjPreClose":21.02,"postHourTrading":{"tag":"盘后","latestPrice":21.02,"preClose":21.02,"latestTime":"19:30 EST","volume":4033,"amount":84773.24,"timestamp":1794270600885,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4488975609585906,"impliedVol":0.6931,"impliedVolPercentile":0.204},"requestUrl":"/m/hq/s/NVCT","defaultTab":"news","newsList":[{"id":"2681817399","title":"Nuvectis Pharma Insiders Enjoying US$141k Appreciation On US$1.17m Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2681817399","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681817399?lang=en_us&edition=fundamental","pubTime":"2026-11-07 20:23","pubTimestamp":1794054235,"startTime":"0","endTime":"0","summary":"SSimply Wall StNovember 7, 2026","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvct/nuvectis-pharma/news/nuvectis-pharma-insiders-enjoying-us141k-appreciation-on-us1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvct/nuvectis-pharma/news/nuvectis-pharma-insiders-enjoying-us141k-appreciation-on-us1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680705063","title":"Nuvectis Pharma Inc Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2680705063","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680705063?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:31","pubTimestamp":1793802713,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Inc reports results for the quarter ended September 30 - Earnings SummaryNuvectis Pharma IncNVCT.OQreported a quarterly adjusted loss of $1.02 per share for the quarter ended September","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL5N46L24X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680705409","title":"Aprea Therapeutics Q3 Net Loss Widens on Higher R&D Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2680705409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680705409?lang=en_us&edition=fundamental","pubTime":"2026-11-04 21:38","pubTimestamp":1793799511,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Q3 net loss widens on higher R&D spendingOverviewUS precision oncology firm's Q3 net loss widened to $4.8 mlnOperating loss increased to $5.2 mln as R&D expenses rose for lead clini","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","APRE","NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680055796","title":"Nuvectis Pharma Q3 Net Loss Widens on Licensing and R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2680055796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680055796?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:12","pubTimestamp":1793794325,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma Q3 net loss widens on licensing and R&D costsOverviewUS biopharma firm's Q3 net loss widened, driven by upfront licensing payments and higher R&D spendCompany ended Q3 with $140.7 mln ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4505","LU1861559042.SGD","BK4556","BK4585","BK4611","BK4139","CMPS","LU1861558580.USD","BK4588","NVCT","BK4535","BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680055298","title":"Nuvectis Pharma Q3 EPS $(1.02) Misses $(0.24) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2680055298","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680055298?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:11","pubTimestamp":1793794306,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.24) by 325 percent. This is a 131.82 percent decrease over losses of $(0.44) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62859398/nuvectis-pharma-q3-eps-1-02-misses-0-24-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680205324","title":"Nuvectis Pharma Q3 EPS USD -1.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2680205324","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680205324?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:00","pubTimestamp":1793793604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nPLXMDN2NF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680527640","title":"Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2680527640","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680527640?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:00","pubTimestamp":1793793600,"startTime":"0","endTime":"0","summary":"In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company.The ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/04/3395165/0/en/nuvectis-pharma-reports-third-quarter-2026-financial-results-and-business-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7050","BK4139","CDE.AU","SIL","LU1223082196.USD","XME","LU1223083913.SGD","BK4017","CDE","LU1223082519.USD","GDXJ","NVCT","SGDM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680105796","title":"Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2680105796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680105796?lang=en_us&edition=fundamental","pubTime":"2026-11-03 06:00","pubTimestamp":1793656800,"startTime":"0","endTime":"0","summary":"Fort Lee, NJ, Nov.  02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovative","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/02/3393813/0/en/nuvectis-pharma-to-report-third-quarter-2026-financial-results-on-november-4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678192019","title":"Joseph Pantginis Lifts Nuvectis Pharma Price Target to $39 on Strong NXP200 Glioma Data, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2678192019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678192019?lang=en_us&edition=fundamental","pubTime":"2026-10-26 23:35","pubTimestamp":1793028921,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma, boosting the price target to $39.00. Joseph Pantginis has g...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/joseph-pantginis-lifts-nuvectis-pharma-price-target-to-39-on-strong-nxp200-glioma-data-maintains-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/joseph-pantginis-lifts-nuvectis-pharma-price-target-to-39-on-strong-nxp200-glioma-data-maintains-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678019994","title":"Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678019994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678019994?lang=en_us&edition=fundamental","pubTime":"2026-10-26 21:40","pubTimestamp":1793022016,"startTime":"0","endTime":"0","summary":"WSW, NY, October 26th, 2026, FinanceWire Tumors shrank in 22 of 27 patients treated with NXP200 alone. The results give Nuvectis a clinical foundat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/nuvectis-reports-complete-brain-tumor-responses-as-big-pharma-pays-billions-for-cancer-drugs-nasdaq-nvct?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/nuvectis-reports-complete-brain-tumor-responses-as-big-pharma-pays-billions-for-cancer-drugs-nasdaq-nvct?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","BK4139","QQQ","FTEC","QYLG","QQQA","NVIW.SI","MNQmain","NQmain","QLD","QQQM","PSQ","QQQE","TECS","SQQQ","QQQY","TQQQ","QQQJ","03086","ONEQ","QID","IYW","NDX","GPIQ","QDTE","TQQY","NVCT","JEPQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678193429","title":"Nuvectis Reports 40% Response Rate for Nxp200 in Phase 1b High-Grade Glioma Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2678193429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678193429?lang=en_us&edition=fundamental","pubTime":"2026-10-26 20:33","pubTimestamp":1793017985,"startTime":"0","endTime":"0","summary":"Nuvectis Reports 40% Response Rate for NXP200 in Phase 1b High-Grade Glioma StudyNuvectis Pharma reported positive Phase 1b results for NXP200, already presented at the 2026 European Society for Medic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDLbJckL9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","NVCT","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4139","BCDF","LU2210150020.SGD","BK4588","BK4585","IE00BN0W2T93.GBP","BK4112","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","SG9999014021.USD","LU2210149790.SGD","LU0314104364.USD","IE00BQXX3C00.GBP","IE00B64PRP62.GBP","SG9999014013.SGD","LU2095319765.USD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674590998","title":"Nuvectis Pharma to Participate in Maxim Growth Summit 2026 Panel Discussion","url":"https://stock-news.laohu8.com/highlight/detail?id=2674590998","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674590998?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:00","pubTimestamp":1791547249,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma to participate in Maxim Growth Summit 2026 panel discussionNuvectis Pharma will participate in the Maxim Growth Summit 2026 in New York on Oct. 14, 2026.Chairman and CEO Ron Bentsur is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL3s0QSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014021.USD","SG9999014039.USD","NDAQ","BK4588","IE00BQXX3D17.EUR","LU0314104364.USD","IE00BN0W2W23.USD","NVCT","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","BCDF","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","BK4112","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670142512","title":"Nuvectis Oncology Reaffirmed at Buy as Analyst Cites Differentiated BRAF Pipeline and Maintains $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2670142512","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670142512?lang=en_us&edition=fundamental","pubTime":"2026-09-25 23:25","pubTimestamp":1790349951,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $30.00. Naz Rahman h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nuvectis-oncology-reaffirmed-at-buy-as-analyst-cites-differentiated-braf-pipeline-and-maintains-30-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nuvectis-oncology-reaffirmed-at-buy-as-analyst-cites-differentiated-braf-pipeline-and-maintains-30-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670440301","title":"Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2670440301","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670440301?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:30","pubTimestamp":1790339440,"startTime":"0","endTime":"0","summary":"WSW, NY, September 25th, 2026, FinanceWire Three months ago, Nuvectis Pharma (NASDAQ:NVCT) was an oncology developer anchored by a single early-sta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/nuvectis-in-licensed-cancer-drug-earned-breakthrough-designation-in-china-and-its-not-even-their-lead-asset?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/nuvectis-in-licensed-cancer-drug-earned-breakthrough-designation-in-china-and-its-not-even-their-lead-asset?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SQQQ","QDTE","QID","NVCT","NVIW.SI","GPIQ","QLD","MNQmain","QQQE","BK4139","NDX","QQQJ","QYLG","NQmain","FTEC","DBB","TQQY","IYW","TQQQ","JEPQ","03086","QQQM","ONEQ","TECS","PSQ","QQQY",".IXIC","QQQ","QQQA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499252","title":"Nuvectis Pharma Price Target Maintained with a $39.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499252","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499252?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:41","pubTimestamp":1790260860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCT/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669498985","title":"Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2669498985","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669498985?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:37","pubTimestamp":1790253453,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma  said Thursday that China's Center for Drug Evaluation granted Breakthrough Therapy Designation to NXP200 for patients with BRAF V600-mutant, recurrent or progressive high-grade glioma, an aggressive type of brain tumor.The biopharmaceutical company said NXP200 has demonstrated single-agent clinical activity, including in heavily pre-treated patients and patients previously treated with BRAF inhibitors, against primary central nervous system tumors and other tumor types.These include non-small cell lung, colorectal, and papillary thyroid cancers.In June, Nuvectis in-licensed exclusive worldwide rights, excluding Greater China, to NXP200 from Haisco Pharmaceutical Group, the company said.\"The CDE's granting of Breakthrough Therapy Designation underscores the compelling clinical activity observed to date with NXP200 in patients with recurrent or progressive BRAF V600-mutant high-grade glioma,\" Chairman and Chief Executive Ron Bentsur said in a statement.\"In parallel, we c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669460310","title":"Nuvectis Announces Nxp200 Granted Breakthrough Therapy Designation in China for Braf V600-Mutant, Recurrent or Progressive, High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2669460310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669460310?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:00","pubTimestamp":1790251200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA7SSVKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871437","title":"Nuvectis Pharma to Present at H.C. Wainwright Annual Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871437","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871437?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:00","pubTimestamp":1788436843,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma to present at H.C. Wainwright annual investment conferenceNuvectis will present at the 2026 Cantor Global Healthcare Conference on September 11, 2026 at 9:10 a.m. ET.Senior management ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL656ySg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BK4588","BCDF","NDAQ","LU2210150020.SGD","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","NVCT","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","LU0314104364.USD","BK4139","SG9999014021.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","BK4585","IE00BN0W2W23.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877164","title":"Nuvectis Pharma To Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877164","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877164?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:00","pubTimestamp":1788436800,"startTime":"0","endTime":"0","summary":"Fort Lee, NJ, Sept.  03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovativ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3355841/0/en/nuvectis-pharma-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275830","title":"Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275830","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275830?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:15","pubTimestamp":1787570153,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Pete Stavropoulos initiated coverage of Nuvectis Pharma (NVCT) with an Overweight rating. Nuvectis’ NXP100 offers a poten...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvectis.com","stockEarnings":[{"period":"1week","weight":0.0959},{"period":"1month","weight":-0.0047},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.7458},{"period":"1year","weight":2.4235},{"period":"ytd","weight":1.7841}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.130119},{"month":2,"riseRate":0.75,"avgChangeRate":0.147062},{"month":3,"riseRate":0.6,"avgChangeRate":0.077847},{"month":4,"riseRate":0.8,"avgChangeRate":0.055849},{"month":5,"riseRate":0.8,"avgChangeRate":0.192364},{"month":6,"riseRate":0.2,"avgChangeRate":0.054549},{"month":7,"riseRate":0.4,"avgChangeRate":-0.045885},{"month":8,"riseRate":0.6,"avgChangeRate":0.006756},{"month":9,"riseRate":0,"avgChangeRate":-0.094667},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034434},{"month":11,"riseRate":0.4,"avgChangeRate":-0.044822},{"month":12,"riseRate":0.75,"avgChangeRate":0.071233}],"exchange":"NASDAQ","name":"Nuvectis Pharma, Inc.","nameEN":"Nuvectis Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvectis Pharma, Inc.,NVCT,Nuvectis Pharma, Inc.股票,Nuvectis Pharma, Inc.股票老虎,Nuvectis Pharma, Inc.股票老虎国际,Nuvectis Pharma, Inc.行情,Nuvectis Pharma, Inc.股票行情,Nuvectis Pharma, Inc.股价,Nuvectis Pharma, Inc.股市,Nuvectis Pharma, Inc.股票价格,Nuvectis Pharma, Inc.股票交易,Nuvectis Pharma, Inc.股票购买,Nuvectis Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvectis Pharma, Inc.(NVCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvectis Pharma, Inc.(NVCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}